Public Release: 

Insilico to present its latest advances in human aging biomarker development

InSilico Medicine, Inc.


IMAGE: Polina Mamoshina, a Senior Research Scientist at Insilico Medicine, presents "AI for Longevity Biotechnology " at The Investing in the Age of Longevity Conference 2018 in London view more 

Credit: Insilico Medicine

Monday, October 29, 2018 - Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest advances in human aging biomarker development at the Investing in the Age of Longevity Conference in London, 1 of November.

New technologies in Artificial Intelligence (AI) are paving the way for advanced biotechnology research of aging. The presentation will focus on recent developments in biomarkers, using deep learning, blood biochemistry, gene expression, as well as imaging data. It will also cover the application of deep neural networks in drug discovery, including the generation of new models that could target the aging process.

"We are happy to present some of our latest research at the Investing in the Age of Longevity Conference, which gathers the leading longevity scientists and investors. Longevity has fascinated mankind for centuries, and now with the increased scientific understanding of aging we are looking into the longevity industry as one of the greatest investment opportunities of all time," says Polina Mamoshina, a senior research scientist at Insilico Medicine.

Investing in the Age of Longevity brings together all the scientists and business leaders to discuss obstacles and objectives, share and learn the first-hand experience from the experts, as well as help investment companies utilize the scientific expertise in building a solid longevity investment portfolio. The Conference is held on the 1st of November.

For the audience, interested in learning more about the opportunities and challenges of the industry, professor Alex Zhavoronkov, CEO and Founder of Insilico Medicine, will be participating in the panel discussion of the Conference jointly with other experts of the field.


Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine.

For further information, images or interviews, please contact:

Contact: Klug Gehilfer


Official website of the conference: Investing in the Age of Longevity Conference

About Insilico Medicine, Inc

Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video:

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.